News Releases
MSD Animal Health Strengthens Its Dedication to Rabies Elimination with 7 Millionth Vaccine Donation Through the Afya Program
RAHWAY, N.J., Sept. 26, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded.
News Releases
MSD Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress
MSD Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs
News Releases
MSD Animal Health Launches NUMELVI® (atinvicitinib) Tablets for Dogs – A Veterinary Innovation in Fast, Effective and Safe Targeted Itch Relief
MSD Animal Health today announced that the European Commission has approved NUMELVI™ (atinvicitinib) Tablets for Dogs.
News Releases
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New MSD Animal Health Global Survey Finds
Data show pet owners face difficulties with consistent compliance, while veterinarians worry about inconsistent or incorrect medication administration In the U.S. Two-thirds of veterinarians note that most pet owners do not follow year-round treatment plan, despite evidence that fleas and tick are present during all seasons RAHWAY, N.J., August 19, 2025
News Releases
MSD Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress
Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations RAHWAY, N.J., August 18, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will
News Releases
European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs
NUMELVI from MSd Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs
News Releases
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from MSD Animal Health
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to treat and protect dogs from fleas and ticks.
Featured Stories
Big data can carry farming forward. Now more than ever, farmers must embrace it.
To most Americans, farmers remain unseen figures behind the food on their dinner tables — hand-written records, calloused hands, and long days of physical labor.
News Releases
MSD Animal Health Receives Positive Opinion from CVMP for NOBIVAC® L6 and NOBIVAC® LoVo L6 Vaccines for Use in Dogs Against Leptospirosis
Today we announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines for use against leptospirosis in dogs.
News Releases
MSD Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – MSD Animal Health
News Releases
MSD Animal Health Receives Positive CVMP Opinion for INNOVAX®-ND-IBD-ILT for Use in Chickens
MSD Animal Health to Showcase Innovations in Ruminant Health at the World Buiatrics Congress in Cancun, Mexico.
News Releases
MSD Animal Health Demonstrates its Commitment to Ruminant Health at the 2025 European Buiatrics Congress
Presenting more than 10 new studies and continuing to solve unmet medical needs in the Ruminant space. Join us at EBC 2025 in France.